AF710B, a Novel M1/σ1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer's Disease

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neurodegenerative Diseases

• Publication date

  2015-11-26

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1159/000440864PMID 26606130PMCID PMC4803577
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Roles of sigma-1 receptors in Alzheimer's disease.

  2015cited by this paper
• CDK 5 activator protein p 25 preferentially binds and activates GSK 3 β

  2015cited by this paper
• Neuronal Store-Operated Calcium Entry and Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer's Disease

  2015cited by this paper
• Sigma-1 receptor regulates Tau phosphorylation and axon extension by shaping p35 turnover via myristic acid

  2015cited by this paper
• Calcium Signaling, Excitability, and Synaptic Plasticity Defects in a Mouse Model of Alzheimer's Disease

  2015cited by this paper
• Single APP knockin mouse models of Alzheimer’s disease

  2014cited by this paper
• Reduced synaptic STIM2 expression and impaired store-operated calcium entry cause destabilization of mature spines in mutant presenilin mice.

  2014influential reference
• Single App knock-in mouse models of Alzheimer's disease

  2014influential reference
• CDK5 activator protein p25 preferentially binds and activates GSK3β

  2014influential reference
• Cocaine Inhibits Dopamine D2 Receptor Signaling via Sigma-1-D2 Receptor Heteromers

  2013cited by this paper
• Ligand for Translocator Protein Reverses Pathology in a Mouse Model of Alzheimer's Disease

  2013cited by this paper
• Blockade of Tau Hyperphosphorylation and Aβ1–42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer’s Disease

  2013cited by this paper
• Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

  2013cited by this paper
• Elucidating the Triggers, Progression, and Effects of Alzheimer's Disease

  2012cited by this paper
• Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: perspectives and challenges in treatment of Alzheimer’s disease

  2012influential reference
• The sigma-1 receptor: roles in neuronal plasticity and disease.

  2012cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline.

  2011cited by this paper
• Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders

  2011influential reference
• Cyclin-dependent kinases in brain development and disease.

  2011cited by this paper
• AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.

  2010cited by this paper
• The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study.

  2010cited by this paper
• The sigma-1 receptor chaperone as an inter-organelle signaling modulator.

  2010cited by this paper
• Alzheimer's disease.

  2010cited by this paper
• Direct involvement of σ-1 receptors in the dopamine D1 receptor-mediated effects of cocaine

  2010cited by this paper
• Differential effects of allosteric M(1) muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation.

  2010cited by this paper
• High occupancy of sigma1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503.

  2009cited by this paper
• Sigma-1 receptors regulate hippocampal dendritic spine formation via a free radical-sensitive mechanism involving Rac1·GTP pathway

  2009cited by this paper
• Low density of sigma1 receptors in early Alzheimer’s disease

  2008cited by this paper
• Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimer’s disease

  2008cited by this paper
• Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice.

  2008cited by this paper
• High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11C]SA4503.

  2007cited by this paper
• Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival.

  2007cited by this paper
• M1 receptors play a central role in modulating AD-like pathology in transgenic mice.

  2006influential reference
• Survival

  2004cited by this paper
• Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

  2003cited by this paper
• N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity

  2003cited by this paper
• ERKI/II Regulation by the Muscarinic Acetylcholine Receptors in Neurons

  2000cited by this paper
• Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system.

  2000cited by this paper
• Making new connections: role of ERK/MAP kinase signaling in neuronal plasticity.

  1999cited by this paper
• Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice

  1999influential reference
• Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration

  1999cited by this paper
• Selective M1 muscarinic receptor antagonists disrupt memory consolidation of inhibitory avoidance in rats.

  1997cited by this paper
• Ameliorating effect of SA4503, a novel sigma 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats.

  1996cited by this paper
• M1 muscarinic antagonists interact with sigma recognition sites.

  1991cited by this paper
• M1 muscarinic antagonists interact with σ recognition sites

  1991cited by this paper

• Development of Second-Generation Phenoxyethylpiperidines as Potent Sigma-1 Receptor Agonists with Neuroprotective Potential for Alzheimer's Disease.

  2026cites this paper
• Sigma-1 receptor positive allosteric modulator promotes neuronal survival and improves cognitive deficits in AD mice via sigma-1 receptor/ERK pathway.

  2026cites this paper
• Tau-Targeted Therapeutic Strategies: Mechanistic Targets, Clinical Pipelines, and Analysis of Failures

  2025cites this paper
• Sigma-1 Receptor Ligands for CNS Cancer Treatment

  2025cites this paper
• Animal Models for the Study of Neurological Diseases and Their Link to Sleep

  2025cites this paper
• The protective effect of DMT against neurodegeneration.

  2025cites this paper
• Pharmacological and Pathological Implications of Sigma-1 Receptor in Neurodegenerative Diseases

  2025cites this paper
• CNS muscarinic receptors and muscarinic receptor agonists in Alzheimer disease treatment.

  2025cites this paper
• Advancing depression treatment: the role of sigma receptor ligands

  2025cites this paper
• The cholinotrophic system in Down syndrome.

  2025cites this paper
• The involvement of the cholinergic system in Alzheimer disease.

  2025cites this paper
• Ginkgo Biloba as a niche theme cognitive enhancer agent, 1420 dokumen of Scopus database. A bibliometric study from 1988 to 2024

  2025cites this paper
• CNEURO-201, an Anti-amyloidogenic Agent and σ1-Receptor Agonist, Improves Cognition in the 3xTg Mouse Model of Alzheimer’s Disease by Multiple Actions in the Pathology

  2025cites this paper
• Social and contextual memory impairments induced by Amyloid-β oligomers are rescued by Sigma-1 receptor activation.

  2025cites this paper
• Multi-perspective neural network for dual drug repurposing in Alzheimer's disease

  2024cites this paper
• Sigma 1 Receptor and Its Pivotal Role in Neurological Disorders.

  2024cites this paper
• Current Update on Promising New Anti-Alzheimer's Drugs in Different Phases of Clinical Development: Where Exactly Are We Lacking?

  2024cites this paper
• Analysing the effect caused by increasing the molecular volume in M1-AChR receptor agonists and antagonists: a structural and computational study

  2024cites this paper
• Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities

  2024cites this paper
• Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders

  2023cites this paper
• Population‐Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3‐71, a Novel Sigma‐1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease

  2023cites this paper
• Fluoroethylnormemantine (FENM) shows synergistic protection in combination with a sigma-1 receptor agonist in a mouse model of Alzheimer's disease.

  2023cites this paper
• Early treatment with an M1 and sigma-1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology.

  2023cites this paper
• Concentration–QTc Relationship from a Single Ascending Dose Study of ANAVEX3‐71, a Novel Sigma‐1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for the Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer's Disease

  2023cites this paper
• SpineTool is an open-source software for analysis of morphology of dendritic spines

  2023cites this paper
• Hybrid neural network approaches to predict drug–target binding affinity for drug repurposing: screening for potential leads for Alzheimer’s disease

  2023cites this paper
• Chaperone-Dependent Mechanisms as a Pharmacological Target for Neuroprotection

  2023cites this paper
• Alzheimer's disease - Where do we go from here?

  2022cites this paper
• Fenfluramine modulates the anti-amnesic effects induced by sigma-1 receptor agonists and neuro(active)steroids in vivo.

  2022cites this paper
• Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders

  2022cites this paper
• Novel Therapeutic Target for Prevention of Neurodegenerative Diseases: Modulation of Neuroinflammation with Sig-1R Ligands

  2022cites this paper
• Endoplasmic Reticulum-Mitochondria Contacts Modulate Reactive Oxygen Species-Mediated Signaling and Oxidative Stress in Brain Disorders: The Key Role of Sigma-1 Receptor

  2022cites this paper
• Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease

  2022cites this paper
• Current Trends in the Animal Models for Screening of Nootropic Agents.

  2022cites this paper
• Understanding How Physical Exercise Improves Alzheimer’s Disease: Cholinergic and Monoaminergic Systems

  2022cites this paper
• NMDA and AMPA Receptors at Synapses: Novel Targets for Tau and α-Synuclein Proteinopathies

  2022cites this paper
• Discovery of Potent Cholinesterase Inhibition-Based Multi-Target-Directed Lead Compounds for Synaptoprotection in Alzheimer's Disease.

  2022cites this paper
• M1-selective muscarinic allosteric modulation enhances cognitive flexibility and effective salience in nonhuman primates

  2022cites this paper
• Cholinergic basal forebrain degeneration due to sleep-disordered breathing exacerbates pathology in a mouse model of Alzheimer’s disease

  2022cites this paper
• Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer's disease: relevance for precision medicine in neurodegenerative diseases.

  2022cites this paper
• Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids

  2022cites this paper
• The molecular role of Sigmar1 in regulating mitochondrial function through mitochondrial localization in cardiomyocytes.

  2021cites this paper
• Mitochondrial Aspects of Neuronal Pathology in Triple-Transgenic Alzheimer’s Disease Mice

  2021cites this paper
• Multi-Target Directed Ligands (MTDLs) Binding the σ1 Receptor as Promising Therapeutics: State of the Art and Perspectives

  2021cites this paper
• Neuropharmacology of Cevimeline and Muscarinic Drugs—Focus on Cognition and Neurodegeneration

  2021cites this paper
• Tardive neurotoxicity of anticholinergic drugs: A review

  2020cites this paper
• Molecular Dysfunctions of Mitochondria-Associated Membranes (MAMs) in Alzheimer’s Disease

  2020cites this paper
• Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders

  2020cites this paper
• Sigma ligands as potent inhibitors of Aβ and AβOs in neurons and promising therapeutic agents of Alzheimer's disease.

  2020cites this paper
• Iron-responsive-like elements and neurodegenerative ferroptosis

  2020cites this paper
• Cholinergic basal forebrain degeneration due to obstructive sleep apnoea increases Alzheimer’s pathology in mice

  2020cites this paper
• At the Crossing of ER Stress and MAMs: A Key Role of Sigma-1 Receptor?

  2020cites this paper
• Knocking Out Sigma-1 Receptors Reveals Diverse Health Problems

  2020cites this paper
• Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.

  2020cites this paper
• The dialog between neurons and microglia in Alzheimer's disease: The neurotransmitters view

  2020cites this paper
• Antagonist of neuronal store-operated calcium entry exerts beneficial effects in neurons expressing PSEN1ΔE9 mutant linked to familial Alzheimer disease.

  2019cites this paper
• Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia

  2019cites this paper
• Targeting the Iron-Response Elements of the mRNAs for the Alzheimer’s Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity

  2019cites this paper
• Experimental Pharmacology in Transgenic Rodent Models of Alzheimer’s Disease

  2019cites this paper
• Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor.

  2019influential citation
• Mutational Analysis of Sigma-1 Receptor’s Role in Synaptic Stability

  2019cites this paper
• Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases

  2019influential citation
• Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research

  2018cites this paper
• A Meta-Analysis Assessing the Role of Phosphorylated Tau and Amyloid-Beta on Cognitive Decline in a Preclinical Model Of Alzheimer's Disease

  2018cites this paper
• The Basal Forebrain Regulates Global Resting-State fMRI Fluctuations.

  2018cites this paper
• Inhibition of TRPC1-Dependent Store-Operated Calcium Entry Improves Synaptic Stability and Motor Performance in a Mouse Model of Huntington’s Disease

  2018influential citation
• AF710B, an M1/sigma‐1 receptor agonist with long‐lasting disease‐modifying properties in a transgenic rat model of Alzheimer's disease

  2018influential citation
• Sigma-1 Receptor Agonists Induce Oxidative Stress in Mitochondria and Enhance Complex I Activity in Physiological Condition but Protect Against Pathological Oxidative Stress

  2017influential citation
• Alzheimer's Disease: Dawn of a New Era?

  2017cites this paper
• Sigma-1 (σ1) Receptor in Memory and Neurodegenerative Diseases.

  2017cites this paper
• Population-based study suggests an increased risk of Alzheimer’sdisease in Sjögren’s syndrome

  2017cites this paper
• Cognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy

  2017cites this paper
• The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.

  2017cites this paper
• WITHDRAWN: Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research.

  2017cites this paper
• Role of σ1 Receptors in Learning and Memory and Alzheimer's Disease-Type Dementia.

  2017cites this paper
• The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases

  2017cites this paper
• New bifunctional antioxidant/σ1 agonist ligands: Preliminary chemico-physical and biological evaluation.

  2016cites this paper